The Experts below are selected from a list of 1257 Experts worldwide ranked by ideXlab platform
Sarah A Wagner - One of the best experts on this subject based on the ideXlab platform.
-
the effects of Flunixin Meglumine and hoof trimming on lying behavior locomotion and milk production in lame and nonlame lactating dairy cows
Journal of Dairy Science, 2020Co-Authors: N M Chapel, J.m. Young, Sarah A WagnerAbstract:ABSTRACT Hoof trimming is used to prevent and treat lameness in dairy cows; however, hoof trimming itself increases daily time spent lying down, possibly due to discomfort. We hypothesized that treatment of lame and nonlame cows with an anti-inflammatory analgesic drug at the time of hoof trimming would mitigate discomfort, thereby improving locomotion scores and reducing post-trimming increases in lying time. We further hypothesized that drug treatment would improve post-trimming milk production. Our objective was to determine the effects of treatment with the nonsteroidal anti-inflammatory drug Flunixin Meglumine (2.2 mg/kg of BW) at the time of hoof trimming on locomotion, lying times, and milk production in lame and nonlame lactating dairy cows. All cows were filmed for locomotion scoring 1 d before and 1, 8, and 28 d after hoof trimming. Daily time spent standing and lying was recorded for 4 d before and 4 wk after hoof trimming, and daily milk production was recorded for 1 wk before and 8 wk after trimming. Thirty minutes before hoof trimming, an intravenous injection of Flunixin Meglumine (n = 34) or isotonic sterile saline solution (n = 34) was administered to each cow. Then, all cows had their hooves trimmed using the Dutch method. The same treatment was repeated 24 h after hoof trimming. Cows were categorized using baseline locomotion scores as lame (score ≥3/5) or nonlame (score
-
short communication behavioral evaluation of the analgesic effect of Flunixin Meglumine in lame dairy cows
Journal of Dairy Science, 2017Co-Authors: Sarah A Wagner, J.m. Young, J K Tena, B H ManningAbstract:The objective of this study was to evaluate the effect of Flunixin Meglumine treatment on lameness pain in dairy cows. Twenty-four lactating Holstein cows were enrolled in the study based on visual observation of abnormal locomotion. The primary measurement endpoint was weight-shifting between the rear limbs. Weight-shifting was calculated as the standard deviation of the weight borne on the rear limbs over a 15 min period; this value correlates directly with lameness pain in dairy cows. After collecting baseline weight-bearing data, we randomly assigned cows to 1 of 2 treatment groups: 2.2 mg/kg body weight Flunixin Meglumine (2 mL/45 kg) or an equivalent volume of isotonic sterile saline solution. Weight-bearing data were collected from each cow at 2, 6, 12, and 24 h after a single intravenous drug treatment. Mean locomotion scores over the 2 d before treatment were 2.38/5 in the Flunixin-treated group and 2.43/5 in the saline-treated control group; these values were not significantly different. Weight-shifting values were also not significantly different on either pretreatment day. Cows treated with Flunixin Meglumine showed significantly less weight-shifting between the rear limbs at 6, 12, and 24 h after treatment compared with saline-treated controls, providing evidence that Flunixin Meglumine alleviates lameness-associated pain.
-
the effects of Flunixin Meglumine treatment and hoof trimming on lying behavior and locomotion in dairy cows
American Association of Bovine Practitioners Proceedings of the Annual Conference, 2014Co-Authors: N M Chapel, L Hulsman L Hanna, N Chapinal, Sarah A WagnerAbstract:Lameness is a common disorder in US dairy herds and a welfare concern. Compared to non-lame cows, lame cows spend more time lying down. Although regular hoof trimming is often a component of lameness prevention efforts, increased lying time has been observed following hoof trimming, suggesting that it may cause discomfort in dairy cows. Preliminary work suggested that treatment with a non-steroidal anti-inflammatory drug decreases the duration of increased lying time after hoof trimming. The objective of this study was to examine interactions between lameness, hoof trimming, and non-steroidal drug therapy. Our hypothesis was that cows treated with Flunixin Meglumine before and after hoof trimming would spend less time lying, have improved gait scores, and produce more milk than cows that had their hooves trimmed without concurrent drug treatment.
Johann F. Coetzee - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacokinetics and pharmacodynamics of intravenous and transdermal Flunixin Meglumine in meat goats
Journal of veterinary pharmacology and therapeutics, 2019Co-Authors: Emily J. Reppert, Michael D. Kleinhenz, Geraldine Magnin, Pritam K. Sidhu, Yuntao Zhang, Hyun Joo, Shawnee Montgomery, Heather N. Bornheim, Johann F. CoetzeeAbstract:The aim of this study was to determine the pharmacokinetics and prostaglandin E2 (PGE2 ) synthesis inhibiting effects of intravenous (IV) and transdermal (TD) Flunixin Meglumine in eight adult female Boer goats. A dose of 2.2 mg/kg was administered intravenously (IV) and 3.3 mg/kg administered TD using a cross-over design. Plasma Flunixin concentrations were measured by LC-MS/MS. Prostaglandin E2 concentrations were determined using a commercially available ELISA. Pharmacokinetic (PK) analysis was performed using noncompartmental methods. Plasma PGE2 concentrations decreased after Flunixin Meglumine for both routes of administration. Mean λz -HL after IV administration was 6.032 hr (range 4.735-9.244 hr) resulting from a mean Vz of 584.1 ml/kg (range, 357.1-1,092 ml/kg) and plasma clearance of 67.11 ml kg-1 hr-1 (range, 45.57-82.35 ml kg-1 hr-1 ). The mean Cmax , Tmax, and λz -HL for Flunixin following TD administration was 0.134 μg/ml (range, 0.050-0.188 μg/ml), 11.41 hr (range, 6.00-36.00 hr), and 43.12 hr (15.98-62.49 hr), respectively. The mean bioavailability for TD Flunixin was calculated as 24.76%. The mean 80% inhibitory concentration (IC80 ) of PGE2 by Flunixin Meglumine was 0.28 μg/ml (range, 0.08-0.69 μg/ml) and was only achieved with IV formulation of Flunixin in this study. The PK results support clinical studies to examine the efficacy of TD Flunixin in goats. Determining the systemic effects of Flunixin-mediated PGE2 suppression in goats is also warranted.
-
Pharmacokinetics of multiple doses of transdermal Flunixin Meglumine in adult Holstein dairy cows.
Journal of veterinary pharmacology and therapeutics, 2018Co-Authors: Michael D. Kleinhenz, Pritam K. Sidhu, Patrick J. Gorden, Katie E. Kleinhenz, Joe S. Smith, Jennifer A. Schleining, L. L. Wulf, D. Rea, Johann F. CoetzeeAbstract:A transdermal formulation of the nonsteroidal anti-inflammatory drug, Flunixin Meglumine, has been approved in the United States and Canada for single-dose administration. Transdermal Flunixin Meglumine was administered to 10 adult Holstein cows in their second or third lactation at the label dose of 3.33 mg/kg every 24 hr for three total treatments. Plasma Flunixin concentrations were determined using high-pressure liquid chromatography with mass spectroscopy (HPLC-MS). Pharmacokinetic analysis was completed on each individual animal with noncompartmental methods using computer software. The time to maximum drug concentration (Tmax) was 2.81 hr, and the maximum drug concentration was 1.08 μg/ml. The mean terminal half-life (T½) was determined to be 5.20 hr. Clearance per fraction absorbed (Cl/F) was calculated to be 0.294 L/hr kg-1 , and volume of distribution of fraction (Vz/F) absorbed was 2.20 L/kg. The mean accumulation factor was 1.10 after three doses. This indicates changes in dosing may not be required when giving multiple doses of Flunixin transdermal. Further work is required to investigate the clinical efficacy of transdermal Flunixin after multiple daily doses.
-
comparative plasma and interstitial fluid pharmacokinetics of Flunixin Meglumine and ceftiofur hydrochloride following individual and co administration in dairy cows
Journal of Veterinary Pharmacology and Therapeutics, 2018Co-Authors: P J Gorden, Suzanne M. Rajewski, Michael D. Kleinhenz, Larry W Wulf, C Wang, Ronette Gehring, Johann F. CoetzeeAbstract:Ceftiofur (CEF) and Flunixin Meglumine (FLU) are two drugs approved for use in beef and dairy cattle that are frequently used in combination for many diseases. These two drugs are the most commonly used drugs in dairy cattle in their respective drug classes. Two research groups have recently published manuscripts demonstrating altered pharmacokinetics of FLU and CEF in cows affected with naturally occurring mastitis. The objective of this study was to determine whether pharmacokinetics of Flunixin Meglumine administered intravenously or intramuscularly administered ceftiofur hydrochloride would be altered when co-administered versus individual administration to healthy dairy cattle. Ten cows were utilized in a three-period, three-treatment crossover design, with all cows receiving each treatment one time with a 10-day washout period between treatments. Following treatment, plasma and interstitial fluid samples were collected and stored for later analysis. Additionally, plasma ultrafiltrate was collected using microcentrifugation to determine plasma protein binding of each drug. Drug concentrations in plasma, plasma ultrafiltrate, and interstitial fluid were determined using high-pressure liquid chromatography coupled with mass spectrometry. The results of this trial indicate that drug interactions between FLU and CEF do not occur when the two drugs are administered simultaneously in healthy cattle. Further work is needed to determine whether this relationship is maintained in the presence of severe disease.
-
effects of transdermal Flunixin Meglumine on pain biomarkers at dehorning in calves
Journal of Animal Science, 2017Co-Authors: Michael D. Kleinhenz, Nicholas K. Van Engen, Philip Walsh, P J Gorden, Johann F. CoetzeeAbstract:The objective of this study was to evaluate the analgesic properties of transdermal Flunixin Meglumine when given at the time of dehorning on pain biomarkers. Twenty-four weaned male Holstein calves, 6 to 8 wk of age were enrolled into the study. The calves were randomly assigned to 1 of 3 treatment groups: 1) transdermal Flunixin and dehorn (DH-FLU); 2) transdermal Flunixin and sham dehorn (SHAM-FLU); and 3) placebo and dehorn (DH-PLBO). Transdermal Flunixin at a label dose of 3.33 mg/kg (or placebo at an equivalent volume) was administered as a pour-on along the top-line of the calves in each treatment group concurrently with electrocautery dehorning or sham dehorning. Biomarker parameters collected and analyzed included: infrared thermography (IRT), mechanical nociception threshold (MNT), plasma cortisol, and substance P (SP). There were no differences in maximal temperatures detected for the IRT measurements of the medial canthus of the eye for the DH groups. Mean control point MNT measurements at 48 h were 3.14 kgF, 3.46 kgF, and 1.43 kgF for the DH-FLU, Sham-FLU, and DH-PLBO groups, respectively (P = 0.0001). No other differences of MNT were detected between the dehorned groups for the other test sites and time points. Plasma cortisol reached peak concentration at 20 min postdehorning for the DH-FLU and DH-PLBO groups and 10 min for SHAM-FLU group. Peak plasma cortisol concentrations were 32.0 ng/mL, 12.7 ng/mL, and 28.8 ng/mL for the DH-FLU, SHAM-FLU, and DH-PLBO groups, respectively. Cortisol concentrations were lower for the DH-FLU group at 90 min postdehorning compared to the SHAM-FLU and DH-PLBO groups ( = 0.04). Area under the effect curve (AUEC) were similar for all groups ( = 0.93). No statistical differences in SP concentrations between groups were detected for any of the time points. In conclusion, transdermal Flunixin Meglumine given at the time of dehorning did not provide substantial analgesia based on the pain biomarkers investigated. Further investigation into its role as part of a multimodal analgesic plan is warranted.
-
The pharmacokinetics of transdermal Flunixin Meglumine in Holstein calves.
Journal of veterinary pharmacology and therapeutics, 2016Co-Authors: Michael D. Kleinhenz, Suzanne M. Rajewski, Nicholas K. Van Engen, Patrick J. Gorden, Butch Kukanich, Philip Walsh, Johann F. CoetzeeAbstract:This study describes the pharmacokinetics of topical and intravenous (IV) Flunixin Meglumine in Holstein calves. Eight male Holsteins calves, aged 6 to 8 weeks, were administered Flunixin at a dose of 2.2 mg/kg intravenously. Following a 10-day washout period, calves were dosed with Flunixin at 3.33 mg/kg topically (transdermal). Blood samples were collected at predetermined times from 0 to 48 h for the intravenous portions and 0 to 72 h following topical dosing. Plasma drug concentrations were determined using liquid chromatography with mass spectroscopy. Pharmacokinetic analysis was completed using noncompartmental methods. The mean bioavailability of topical Flunixin was calculated to be 48%. The mean AUC for Flunixin was determined to be 13.9 h × ug/mL for IV administration and 10.1 h × ug/mL for topical administration. The mean half-life for topical Flunixin was 6.42 h and 4.99 h for the intravenous route. The Cmax following topical application of Flunixin was 1.17 μg/mL. The time to maximum concentration was 2.14 h. Mean residence time (MRT) following IV injection was 4.38 h and 8.36 h after topical administration. In conclusion, Flunixin when administered as a topical preparation is rapidly absorbed and has longer half-life compared to IV administration.
Steven R. Hollingsworth - One of the best experts on this subject based on the ideXlab platform.
-
Distribution of Flunixin Meglumine and firocoxib into aqueous humor of horses.
Journal of veterinary internal medicine, 2011Co-Authors: Hugo G. Hilton, K G Magdesian, Allyson D. Groth, Heather K Knych, Scott D Stanley, Steven R. HollingsworthAbstract:Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used systemically for the treatment of inflammatory ocular disease in horses. However, little information exists regarding the ocular penetration of this class of drugs in the horse. Objective: To determine the distribution of orally administered Flunixin Meglumine and firocoxib into the aqueous humor of horses. Animals: Fifteen healthy adult horses with no evidence of ophthalmic disease. Methods: Horses were randomly assigned to a control group and 2 treatment groups of equal sizes (n = 5). Horses assigned to the treatment groups received an NSAID (Flunixin Meglumine, 1.1 mg/kg PO q24h or firocoxib, 0.1 mg/kg PO q24h for 7 days). Horses in the control group received no medications. Concentrations of Flunixin Meglumine and firocoxib in serum and aqueous humor and prostaglandin (PG) E2 in aqueous humor were determined on days 1, 3, and 5 and aqueous : serum ratios were calculated. Results: Firocoxib penetrated the aqueous humor to a significantly greater extent than did Flunixin Meglumine at days 3 and 5. Aqueous : serum ratios were 3.59 ± 3.32 and 11.99 ± 4.62% for Flunixin Meglumine and firocoxib, respectively. Ocular PGE2 concentrations showed no differences at any time point among study groups. Conclusions and Clinical Importance: Both Flunixin Meglumine and firocoxib penetrated into the aqueous humor of horses. This study suggests that orally administered firocoxib penetrates the aqueous humor better than orally administered Flunixin Meglumine at label dosages in the absence of ocular inflammation. Firocoxib should be considered for the treatment of inflammatory ophthalmic lesions in horses at risk for the development of adverse effects associated with nonselective NSAID administration.
Heather K Knych - One of the best experts on this subject based on the ideXlab platform.
-
pharmacokinetics of transdermal Flunixin Meglumine and effects on biomarkers of inflammation in horses
Journal of Veterinary Pharmacology and Therapeutics, 2021Co-Authors: Heather K Knych, D S Mckemie, Rick M Arthur, Sophie R Gretler, Skyler Goldin, Philip H KassAbstract:Flunixin Meglumine is a highly efficacious nonsteroidal anti-inflammatory drug commonly used in equine medicine and especially in performance horses. Recently, a new transdermal Flunixin Meglumine product has been approved for use in cattle. Although not currently approved for use in the horse, the convenience of this product may prove appealing for use in horses, warranting study. Six horses were administered a single transdermal dose of 500 mg and blood and urine samples collected for up to 96 h post-administration. Serum for determination of thromboxane concentrations and whole blood samples was collected at various time and challenged with lipopolysaccharide, calcium ionophore, or methanol to induce ex vivo synthesis of eicosanoids. Concentrations of Flunixin, 5-OH Flunixin, and eicosanoids were measured using LC-MS/MS and non-compartmental pharmacokinetic analysis performed on concentration data. Serum concentrations of Flunixin and 5-OH Flunixin were above the limit of quantitation at 96 h post-administration in both serum and urine. The mean (range) for Cmax , Tmax and the terminal half-life were 515.6 (369.7-714.0) ng/ml, 8.67 (8.0 12.0) h, and 22.4 (18.3-42.5) h, respectively. Following transdermal administration, based on effects on eicosanoid synthesis, Flunixin Meglumine inhibited cyclooxygenase 1 and 2 and 15-lipooxygenase activity, with anti-inflammatory effects lasting for 24-72 h.
-
identification and characterization of the enzymes responsible for the metabolism of the non steroidal anti inflammatory drugs Flunixin Meglumine and phenylbutazone in horses
Journal of Veterinary Pharmacology and Therapeutics, 2021Co-Authors: Heather K Knych, Carrie J Finno, Russell Baden, Rick Arthur, D S MckemieAbstract:The in vivo metabolism and pharmacokinetics of Flunixin Meglumine and phenylbutazone have been extensively characterized; however, there are no published reports describing the in vitro metabolism, specifically the enzymes responsible for the biotransformation of these compounds in horses. Due to their widespread use and, therefore, increased potential for drug-drug interactions and widespread differences in drug disposition, this study aims to build on the limited current knowledge regarding P450-mediated metabolism in horses. Drugs were incubated with equine liver microsomes and a panel of recombinant equine P450s. Incubation of phenylbutazone in microsomes generated oxyphenbutazone and gamma-hydroxy phenylbutazone. Microsomal incubations with Flunixin Meglumine generated 5-OH Flunixin, with a kinetic profile suggestive of substrate inhibition. In recombinant P450 assays, equine CYP3A97 was the only enzyme capable of generating oxyphenbutazone while several members of the equine CYP3A family and CYP1A1 were capable of catalyzing the biotransformation of Flunixin to 5-OH Flunixin. Flunixin Meglumine metabolism by CYP1A1 and CYP3A93 showed a profile characteristic of biphasic kinetics, suggesting two substrate binding sites. The current study identifies specific enzymes responsible for the metabolism of two NSAIDs in horses and provides the basis for future study of drug-drug interactions and identification of reasons for varying pharmacokinetics between horses.
-
pharmacokinetics and anti inflammatory effects of Flunixin Meglumine as a sole agent and in combination with phenylbutazone in exercised thoroughbred horses
Equine Veterinary Journal, 2021Co-Authors: Heather K Knych, Russell Baden, D S Mckemie, Rick M Arthur, Kelsey Seminoff, Philip H KassAbstract:Background Flunixin Meglumine (FM) and phenylbutazone (PBZ) are potent anti-inflammatory agents and as such their potential to mask injuries that would otherwise keep a horse from training or racing is concerning. A common practice in racetrack medicine in the USA is to administer the two drugs within close proximity (24 hours apart) of each other, raising the concern of pharmacokinetic interactions and enhanced anti-inflammatory effects. Objectives Describe the pharmacokinetics and effects of PBZ on the clearance of FM when administered in close proximity as well as effects on inflammatory mediators. Study design Two-way randomised balanced crossover experiment. Methods Twelve Thoroughbred exercised horses received 500 mg FM IV alone or in combination with 2 g of IV PBZ 24 hours later. Blood and urine samples were collected prior to and for up to 120 hours post-drug administration. Whole blood samples were collected at various times and challenged with lipopolysaccharide or calcium ionophore to induce ex vivo synthesis of eicosanoids. Concentrations of FM, PBZ and eicosanoids were measured using LC-MS/MS and noncompartmental pharmacokinetic analysis performed on concentration data. Results Flunixin Meglumine clearance was significantly increased when horses received PBZ 24 hours post-administration (P = .03). No other differences in pharmacokinetic parameters were noted between groups. Thromboxane B2 was significantly suppressed, relative to baseline for 96 hours post-FM administration. Subsequent administration of PBZ prolonged the suppression. Prostaglandin E2 was decreased for 24 hours following administration of FM with subsequent administration of PBZ prolonging the suppression until 120 hours. PGF2alpha concentrations were decreased for up to 168 hours post-FM administration. FM administration significantly decreased 15-HETE. Main limitations Small sample size and lack of a phenylbutazone-only treatment group. Conclusions Administration of PBZ post-FM administration increased FM clearance. The anti-inflammatory effects of FM appear to be prolonged when PBZ is administered 24 hours post-administration.
-
Distribution of Flunixin Meglumine and firocoxib into aqueous humor of horses.
Journal of veterinary internal medicine, 2011Co-Authors: Hugo G. Hilton, K G Magdesian, Allyson D. Groth, Heather K Knych, Scott D Stanley, Steven R. HollingsworthAbstract:Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used systemically for the treatment of inflammatory ocular disease in horses. However, little information exists regarding the ocular penetration of this class of drugs in the horse. Objective: To determine the distribution of orally administered Flunixin Meglumine and firocoxib into the aqueous humor of horses. Animals: Fifteen healthy adult horses with no evidence of ophthalmic disease. Methods: Horses were randomly assigned to a control group and 2 treatment groups of equal sizes (n = 5). Horses assigned to the treatment groups received an NSAID (Flunixin Meglumine, 1.1 mg/kg PO q24h or firocoxib, 0.1 mg/kg PO q24h for 7 days). Horses in the control group received no medications. Concentrations of Flunixin Meglumine and firocoxib in serum and aqueous humor and prostaglandin (PG) E2 in aqueous humor were determined on days 1, 3, and 5 and aqueous : serum ratios were calculated. Results: Firocoxib penetrated the aqueous humor to a significantly greater extent than did Flunixin Meglumine at days 3 and 5. Aqueous : serum ratios were 3.59 ± 3.32 and 11.99 ± 4.62% for Flunixin Meglumine and firocoxib, respectively. Ocular PGE2 concentrations showed no differences at any time point among study groups. Conclusions and Clinical Importance: Both Flunixin Meglumine and firocoxib penetrated into the aqueous humor of horses. This study suggests that orally administered firocoxib penetrates the aqueous humor better than orally administered Flunixin Meglumine at label dosages in the absence of ocular inflammation. Firocoxib should be considered for the treatment of inflammatory ophthalmic lesions in horses at risk for the development of adverse effects associated with nonselective NSAID administration.
L H Baumgard - One of the best experts on this subject based on the ideXlab platform.
-
effects of Flunixin Meglumine on pyrexia and bioenergetic variables in postparturient dairy cows
Journal of Dairy Science, 2009Co-Authors: G Shwartz, K L Hill, M J Vanbaale, L H BaumgardAbstract:Abstract Study objectives were to determine whether a nonsteroidal antiinflammatory drug would reduce parturition-induced inflammation and fever and consequently improve appetite, bioenergetic parameters, and production variables in transitioning dairy cows. Multiparous cows (n = 26) were randomly assigned to 1 of 2 treatments beginning at parturition: 1) Flunixin Meglumine (FM; 2.2mg/kg of BW; Banamine, 50mg/mL, Schering-Plough Animal Health, Kenilworth, NJ), or 2) saline (control) at 2.0 mL/45.5kg of BW. All treatments were administrated i.v. daily for the first 3 d in milk (DIM). Individual milk yield and dry matter intake (DMI) were recorded daily for the first 35 DIM. Rectal temperature was measured daily at 0700 and 1600h for the first 7 DIM. Milk composition was determined on 2, 7, 14, 21, 28, and 35 DIM and blood plasma was collected on 1, 2, 3, 4, 7, 14, 21, 28, and 35 DIM. Body weight and body condition score were determined on −7, 1, 7, 14, 21, 28, and 35 DIM. Flunixin Meglumine treatment slightly increased rectal temperature (38.99 vs. 38.76°C) during the first 7 DIM and reduced overall DMI (22.04 vs. 19.48kg/d), but there were no treatment differences in overall milk yield (35.2kg/d), 3.5% fat-corrected milk (37.6kg/d), energy-corrected milk (37.7kg/d), DMI (2.97% of BW), or overall energy balance (−2.32 Mcal/d). There were no treatment differences in milk fat (3.91%), protein (3.32%), or lactose (4.57%). Treatment had no effect on plasma glucose (66.5mg/dL) or nonesterified fatty acids (553 μ Eq/L), but plasma urea nitrogen tended to be less in FM-treated cows (16.4 vs. 14.5mg/dL). Daily FM administration to cows for the first 3 d after parturition slightly increased rectal temperatures by 0.23°C, reduced feed intake, and did not improve production or energetic variables during the first 35 DIM in transition dairy cows.
-
effects of Flunixin Meglumine on pyrexia and bioenergetic variables in postparturient dairy cows
Journal of Dairy Science, 2009Co-Authors: G Shwartz, K L Hill, M J Vanbaale, L H BaumgardAbstract:Study objectives were to determine whether a nonsteroidal antiinflammatory drug would reduce parturition-induced inflammation and fever and consequently improve appetite, bioenergetic parameters, and production variables in transitioning dairy cows. Multiparous cows (n = 26) were randomly assigned to 1 of 2 treatments beginning at parturition: 1) Flunixin Meglumine (FM; 2.2 mg/kg of BW; Banamine, 50 mg/mL, Schering-Plough Animal Health, Kenilworth, NJ), or 2) saline (control) at 2.0 mL/45.5 kg of BW. All treatments were administrated i.v. daily for the first 3 d in milk (DIM). Individual milk yield and dry matter intake (DMI) were recorded daily for the first 35 DIM. Rectal temperature was measured daily at 0700 and 1600 h for the first 7 DIM. Milk composition was determined on 2, 7, 14, 21, 28, and 35 DIM and blood plasma was collected on 1, 2, 3, 4, 7, 14, 21, 28, and 35 DIM. Body weight and body condition score were determined on -7, 1, 7, 14, 21, 28, and 35 DIM. Flunixin Meglumine treatment slightly increased rectal temperature (38.99 vs. 38.76 degrees C) during the first 7 DIM and reduced overall DMI (22.04 vs. 19.48 kg/d), but there were no treatment differences in overall milk yield (35.2 kg/d), 3.5% fat-corrected milk (37.6 kg/d), energy-corrected milk (37.7 kg/d), DMI (2.97% of BW), or overall energy balance (-2.32 Mcal/d). There were no treatment differences in milk fat (3.91%), protein (3.32%), or lactose (4.57%). Treatment had no effect on plasma glucose (66.5 mg/dL) or nonesterified fatty acids (553 microEq/L), but plasma urea nitrogen tended to be less in FM-treated cows (16.4 vs. 14.5 mg/dL). Daily FM administration to cows for the first 3 d after parturition slightly increased rectal temperatures by 0.23 degrees C, reduced feed intake, and did not improve production or energetic variables during the first 35 DIM in transition dairy cows.